Does Muscle Composition Identify High-Risk Individuals in Chronic Kidney Disease? New AMRA Medical Study Says Yes, Reveals Strong Link to Mortality

Contributed by: Business Wire

Logo

Images

AMRA's MRI-based muscle biomarkers in clinical trials

Business Wire embedded0

Tags

Research

Clinical Trials

Professional Services

Biotechnology

Other Health

Radiology

Health

Data Analytics

Science

More Like This

AMRA's muscle biomarkers - Research study explore changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI)

Decoding Duchenne Muscular Dystrophy: MRI Study Explores the Relationship Between AMRA’s Muscle Biomarkers and Functional Changes in Individuals With DMD

A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol (Photo: Business Wire)

Baseline Enrollment Completed for AMRA Medical and Linköping University’s Landmark Liver Disease Study

Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher

AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity

New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence

MRI-based muscle assessment - Determining the relationship between drug-induced weight reduction and muscle health (Photo: Business Wire)

Adapting To Change: New Focused Review in Circulation Explores The Relationship Between Weight Reduction and Muscle Health

AMRA® Profiler 4 provides rapid and precise body composition measurements in relation to normative data, contextualizing insights at the individual patient level, with high accuracy. (Graphic: Business Wire)

AMRA Medical Secures European Medical Device Regulation Certificate for AMRA® Profiler 4, Highlighting Yet Another Regulatory Win

AMRA Medical's Personalized Fat Z-scores (Photo: Business Wire)

AMRA Medical’s Innovative Fat Z-Score Biomarkers Show Tirzepatide Treatment is Associated with a Potential Targeted Effect on Visceral Fat and Liver Fat

AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’